tyrphostin ag 1024 has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 1 studies
tyrphostin AG 1024: modulates radiosensitivity in human breast cancer cells; also an IGF1 receptor inhibitor
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weston, VJ | 1 |
| Wei, W | 1 |
| Stankovic, T | 1 |
| Kearns, P | 1 |
1 other study available for tyrphostin ag 1024 and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation of STAT6 and PDAP1.
Topics: Butadienes; Cell Cycle; Chromones; Daunorubicin; Down-Regulation; Drug Synergism; Gene Expression Pr | 2018 |